| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EPLIN |
| Uniprot No | Q9UHB6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-598aa |
| 氨基酸序列 | MENCLGESRHEVEKSEISENTDASGKIEKYNVPLNRLKMMFEKGEPTQTKILRAQSRSASGRKISENSYSLDDLEIGPGQLSSSTFDSEKNESRRNLELPRLSETSIKDRMAKYQAAVSKQSSSTNYTNELKASGGEIKIHKMEQKENVPPGPEVCITHQEGEKISANENSLAVRSTPAEDDSRDSQVKSEVQQPVHPKPLSPDSRASSLSESSPPKAMKFQAPARETCVECQKTVYPMERLLANQQVFHISCFRCSYCNNKLSLGTYASLHGRIYCKPHFNQLFKSKGNYDEGFGHRPHKDLWASKNENEEILERPAQLANARETPHSPGVEDAPIAKVGVLAASMEAKASSQQEKEDKPAETKKLRIAWPPPTELGSSGSALEEGIKMSKPKWPPEDEISKPEVPEDVDLDLKKLRRSSSLKERSRPFTVAASFQSTSVKSPKTVSPPIRKGWSMSEQSEESVGGRVAERKQVENAKASKKNGNVGKTTWQNKESKGETGKRSKEGHSLEMENENLVENGADSDEDDNSFLKQQSPQEPKSLNWSSFVDNTFAEEFTTQNQKSQDVELWEGEVVKELSVEEQIKRNRYYDEDEDEE |
| 分子量 | 91.52 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人EPLIN蛋白的假设参考文献示例：
1. **文献名称**：*"Recombinant Human EPLIN Inhibits Tumor Cell Migration by Modulating Actin Dynamics"*
**作者**：Zhang Y. et al.
**摘要**：研究通过体外实验证明，重组人EPLIN蛋白能够与细胞骨架蛋白结合，抑制肿瘤细胞的迁移和侵袭，提示其在癌症治疗中的潜在应用。
2. **文献名称**：*"Expression and Structural Characterization of Recombinant EPLIN for Functional Studies"*
**作者**：Smith J.R. et al.
**摘要**：报道了通过大肠杆菌系统高效表达并纯化重组人EPLIN蛋白的方法，结合X射线晶体学解析其结构，为后续功能研究奠定基础。
3. **文献名称**：*"EPLIN-β Isoform Suppresses Epithelial-Mesenchymal Transition in Cancer Cells via Stabilizing Adherens Junctions"*
**作者**：Wang L. et al.
**摘要**：聚焦于EPLIN-β亚型，发现重组蛋白可通过增强细胞间黏附连接稳定性，抑制上皮-间质转化(EMT)，从而阻碍肿瘤转移。
4. **文献名称**：*"Mechanistic Insights into EPLIN's Role in Cytoskeletal Regulation through Recombinant Protein Mutagenesis"*
**作者**：Lee S. et al.
**摘要**：利用点突变重组人EPLIN蛋白，揭示其特定结构域在调控细胞骨架重塑和应力纤维形成中的关键作用。
(注：上述文献为假设示例，实际研究中请通过学术数据库验证。)
Recombinant human EPLIN (Epithelial Protein Lost in Neoplasm) is a protein of significant interest in cancer and cell biology research. EPLIN, encoded by the *LIMA1* gene, exists as two isoforms (EPLIN-α and EPLIN-β) generated by alternative splicing. It acts as a cytoskeletal regulator, linking membrane-associated proteins to the actin cytoskeleton, thereby influencing cell adhesion, motility, and morphology. EPLIN is notably downregulated in various cancers, including prostate, breast, and gastric cancers, correlating with tumor progression, metastasis, and poor prognosis. Its tumor-suppressive role involves stabilizing adherens junctions, inhibiting epithelial-mesenchymal transition (EMT), and antagonizing Wnt/β-catenin signaling.
The recombinant form, produced via bacterial or eukaryotic expression systems, enables functional studies and therapeutic exploration. Its purity and bioactivity make it valuable for in vitro and in vivo assays, such as examining interactions with cytoskeletal components (e.g., α-catenin, F-actin) or testing its potential to suppress invasive cancer phenotypes. Recombinant EPLIN also holds promise for developing targeted therapies, such as peptide mimics or gene delivery strategies to restore its expression in malignancies. Challenges include optimizing stability and delivery mechanisms for clinical applications. Overall, recombinant EPLIN serves as a critical tool for unraveling tumor biology and advancing anticancer interventions.
×
